MedPath

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
First Posted Date
2019-01-15
Last Posted Date
2021-12-28
Lead Sponsor
Allergan
Target Recruit Count
323
Registration Number
NCT03804268
Locations
🇺🇸

American Institute of Research, Los Angeles, California, United States

🇺🇸

Eye Research Foundation, Newport Beach, California, United States

🇺🇸

Danbury Eye Physicians and Surgeons P.C., Danbury, Connecticut, United States

and more 33 locations

A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation

Phase 4
Completed
Conditions
Lip Augmentation
Interventions
Device: Juvéderm® VOLIFT™ with Lidocaine
First Posted Date
2019-01-08
Last Posted Date
2021-07-28
Lead Sponsor
Allergan
Target Recruit Count
60
Registration Number
NCT03796728
Locations
🇵🇹

Clinica Milenio, Lisbon, Portugal

🇵🇹

Clínica Secret Beauty, Lisbon, Portugal

🇬🇧

Medical and Cosmetic Clinic, Edinburgh, United Kingdom

and more 1 locations

Diabetic Gastroparesis Study 05

Phase 3
Terminated
Conditions
Gastroparesis
Interventions
First Posted Date
2018-12-26
Last Posted Date
2021-12-15
Lead Sponsor
Allergan
Target Recruit Count
202
Registration Number
NCT03786380
Locations
🇺🇸

Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States

and more 480 locations

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Phase 3
Completed
Conditions
Episodic Migraine
Interventions
Drug: Placebo
Drug: Atogepant
First Posted Date
2018-12-17
Last Posted Date
2021-07-09
Lead Sponsor
Allergan
Target Recruit Count
910
Registration Number
NCT03777059
Locations
🇺🇸

Advanced Research Associates, Glendale, Arizona, United States

🇺🇸

Orange Grove Family Practice, Tucson, Arizona, United States

🇺🇸

Principals Research Group, Hot Springs, Arkansas, United States

and more 127 locations

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

Completed
Conditions
Skin Care
Interventions
Device: Skin Imaging
Other: Facial Cleanser
First Posted Date
2018-12-06
Last Posted Date
2019-10-31
Lead Sponsor
Allergan
Target Recruit Count
99
Registration Number
NCT03767400
Locations
🇺🇸

Skinmedica Clinical Research and Innovation Center, Irvine, California, United States

JUVÉDERM® VOLITE™ XC for Cheek Skin Smoothness

Not Applicable
Completed
Conditions
Skin Smoothness of the Cheeks
Interventions
Device: JUVÉDERM VOLITE™ XC
First Posted Date
2018-11-02
Last Posted Date
2022-12-19
Lead Sponsor
Allergan
Target Recruit Count
209
Registration Number
NCT03728309
Locations
🇺🇸

Ava MD, Santa Monica, California, United States

🇺🇸

Facial Plastic Surgery Center /ID# 234876, Baltimore, Maryland, United States

🇺🇸

Dallas Center for Dermatology and Aesthetics /ID# 234452, Dallas, Texas, United States

and more 11 locations

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

Phase 3
Completed
Conditions
Jawline Definition
Interventions
Device: VOLUX XC
Other: No-treatment control
First Posted Date
2018-10-19
Last Posted Date
2023-01-04
Lead Sponsor
Allergan
Target Recruit Count
206
Registration Number
NCT03712137
Locations
🇺🇸

Center aesthetic and dermatology, New York, New York, United States

🇺🇸

Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States

🇺🇸

DeNova Research dba Arano, LLC, Chicago, Illinois, United States

and more 16 locations

A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment

Phase 4
Completed
Conditions
Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality
Interventions
Device: JUVÉDERM®
Drug: BOTOX Cosmetic®
Drug: BELKYRA®
Other: SkinMedica
First Posted Date
2018-10-19
Last Posted Date
2023-10-31
Lead Sponsor
Allergan
Target Recruit Count
59
Registration Number
NCT03712449
Locations
🇨🇦

Project Skin MD Vancouver, Vancouver, British Columbia, Canada

🇨🇦

Pacific Derm, Vancouver, British Columbia, Canada

🇨🇦

Carruthers & Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada

and more 4 locations

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Phase 3
Completed
Conditions
Episodic Migraine
Interventions
Drug: Standard of Care (SOC) Migraine Preventive Medication
Drug: Atogepant
First Posted Date
2018-10-09
Last Posted Date
2021-06-15
Lead Sponsor
Allergan
Target Recruit Count
744
Registration Number
NCT03700320
Locations
🇺🇸

iResearch Atlanta, Decatur, Georgia, United States

🇺🇸

FutureSearch Trials of Dallas, LP, Dallas, Texas, United States

🇺🇸

Rapid Medical Research, Inc., Cleveland, Ohio, United States

and more 98 locations

Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

Terminated
Conditions
Submental Fullness
Interventions
First Posted Date
2018-10-01
Last Posted Date
2020-12-07
Lead Sponsor
Allergan
Target Recruit Count
71
Registration Number
NCT03691415
Locations
🇰🇷

Oracle-Dermatology, Daejeon, Korea, Republic of

🇰🇷

(Apgujeong) Oracle-Dermatology, Seoul, Korea, Republic of

🇰🇷

Dream-Dermatology, Seoul, Korea, Republic of

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath